GLP-1 Agonists in Chronic Kidney Disease

FLOW trial design

FLOW (Perkovic et al., NEJM 2024) was a randomized, double-blind, placebo-controlled trial in 3,533 adults with T2D and CKD (eGFR 25-75 with UACR >100 mg/g, or eGFR 25-50 with UACR 50-5,000)¹. Participants were randomized 1:1 to once-weekly semaglutide titrated to 1.0 mg or placebo, on standard-of-care therapy with RAS blockers and, in eligible patients, SGLT2 inhibitors.

The primary outcome was a composite of kidney failure (dialysis, transplantation, persistent eGFR <15), persistent ≥50% decrease in eGFR, kidney-related death, or cardiovascular death. The trial was designed to detect a 20% relative risk reduction.

Primary outcome

After median 3.4 years follow-up, the primary composite outcome occurred in 331 patients in semaglutide vs 410 in placebo (HR 0.76; 95% CI 0.66-0.88; P<0.001)¹. The trial was stopped early at data monitoring committee recommendation. Individual components all favored semaglutide. Relative risk reduction was consistent across baseline eGFR strata. Number needed to treat over the trial duration: approximately 22.

Cardiovascular and mortality outcomes

Secondary outcomes: semaglutide reduced MACE (HR 0.82) and all-cause death (HR 0.80) vs placebo. The annual eGFR slope was less steep in semaglutide, with a difference of approximately 1.16 mL/min/1.73 m²/year favoring semaglutide¹. These findings extend cardiovascular benefit from SUSTAIN-6 to a higher-baseline-risk population.

Mechanism: how GLP-1 agonism benefits kidneys

Three converging mechanisms: reductions in body weight and blood pressure (lowering glomerular hyperfiltration); improved glycemic control (reducing diabetic kidney damage); and direct anti-inflammatory and antifibrotic effects mediated through GLP-1 receptors on renal tubular cells and proximal vasculature².

Albuminuria reductions in FLOW (35% vs placebo at week 26) suggest renoprotection begins early and is sustained, similar in time course to SGLT2 inhibitors. The mechanisms appear additive to SGLT2 inhibition, supporting combination therapy in appropriate patients.

Dosing in renal impairment

FDA labels for semaglutide, tirzepatide, and liraglutide do not require dose adjustment in mild, moderate, or severe renal impairment³&sup4;. None of these molecules is significantly cleared by the kidneys. They are not removed by hemodialysis.

Caution is appropriate during dose escalation in CKD due to higher risk of dehydration-related AKI from GI symptoms. Slow titration and proactive fluid management reduce this risk.

Related editorial coverage

• FLOW trial — full deep dive
• SELECT cardiovascular outcomes
• GLP-1 in older adults

Frequently asked questions

Can I take semaglutide with kidney disease?

Yes. FLOW demonstrated benefit in patients with T2D and CKD; no dose adjustment is required across the range of renal function studied. Pause therapy and rehydrate during acute illness.

Does Wegovy work for kidney disease?

FLOW used semaglutide 1.0 mg (Ozempic dose). Wegovy 2.4 mg has not been studied in dedicated CKD trials, but the molecular pharmacology is identical; renal benefit is plausibly extrapolable but not formally proven for the higher dose.

Can I combine GLP-1 and SGLT2 inhibitor?

Yes. Combination therapy is increasingly common in T2D and CKD. Mechanisms appear complementary; safety has been favorable in observational data and trial subgroups.

Minimum eGFR for semaglutide?

No labeled minimum eGFR cutoff. Dose adjustment not required even in severe renal impairment. Clinical judgment in patients near or on dialysis.

Does tirzepatide protect kidneys like semaglutide?

Tirzepatide-specific CKD outcomes trials are underway. SURPASS-4 data showed albuminuria reduction and preserved eGFR slope. A dedicated CKD-outcomes trial comparable to FLOW has not yet completed.